fluorouracil and perifosine

fluorouracil has been researched along with perifosine in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ1
Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG1
He, N; Lv, Z; Wang, S; Zhao, W1
Imano, M; Morii, Y; Nishida, S; Otubo, R; Satou, T; Seki, S; Shimomura, K; Takeda, T; Tsubaki, M; Yamatomo, Y1

Trials

1 trial(s) available for fluorouracil and perifosine

ArticleYear
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-20, Volume: 29, Issue:33

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Phosphorylcholine

2011

Other Studies

3 other study(ies) available for fluorouracil and perifosine

ArticleYear
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
    Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic

2012
MicroRNA analysis of NCI-60 human cancer cells indicates that miR-720 and miR-887 are potential therapeutic biomarkers for breast cancer.
    Drug discoveries & therapeutics, 2020, Sep-08, Volume: 14, Issue:4

    Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Genetic; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Phosphorylcholine; Survival Analysis; Up-Regulation

2020
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
    European journal of pharmacology, 2021, May-05, Volume: 898

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caco-2 Cells; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mutation; Oxaliplatin; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction

2021